KRAS and cancer: Both adagrasib and sotorasib are developed to target the KRAS(G12C)-mutant by covalently binding to the mutant cysteine residue in KRAS(G12C), leading to irreversible inhibition of the KRAS activity and blocking KRAS downstream signaling pathways essential for cancer cell proliferation.